Pancreatic cancer-derived organoids – a disease modeling tool to predict drug response

MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In Vivo

(2019) Karolin Walter et al.   Stem Cells International

Patient-derived organoid models help define personalized management of gastrointestinal cancer

(2018) M. R. Aberle et al.   BRITISH JOURNAL OF SURGERY

Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression

(2018) Takashi Seino et al.   Cell Stem Cell

Organoid profiling identifies common responders to chemotherapy in pancreatic cancer

(2018) Hervé Tiriac et al.   Cancer Discovery

Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors

(2018) Isabel Romero-Calvo et al.   MOLECULAR CANCER RESEARCH

Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes

(2018) Sebastian Mueller et al.   NATURE

Organoidomics — falling star or new galaxy in pancreatic cancer?

(2018) Thomas Seufferlein et al.   Nature Reviews Gastroenterology & Hepatology

Thirty-eight-negative kinase 1 mediates trauma-induced intestinal injury and multi-organ failure

(2018) Milena Armacki et al.   JOURNAL OF CLINICAL INVESTIGATION

Importance of organoids for personalized medicine

(2018) Lukas Perkhofer et al.   Personalized Medicine

Molecular Subtyping of Pancreatic Cancer: Translating Genomics and Transcriptomics into the Clinic

(2017) Yongxing Du et al.   Journal of Cancer

Precision medicine in pancreatic cancer — fact or fiction?

(2016) Thomas Seufferlein et al.   Nature Reviews Gastroenterology & Hepatology

Stem cell-derived organoids to model gastrointestinal facets of cystic fibrosis

(2016) Meike Hohwieler et al.   United European Gastroenterology Journal

S3-Leitlinie zum exokrinen Pankreaskarzinom

(2016) T. Seufferlein et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

Organoid Models of Human and Mouse Ductal Pancreatic Cancer

(2015) Sylvia F. Boj et al.   CELL

Whole genomes redefine the mutational landscape of pancreatic cancer

(2015) Nicola Waddell et al.   NATURE

Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell– and patient-derived tumor organoids

(2015) Ling Huang et al.   NATURE MEDICINE

Loss of ATM accelerates pancreatic cancer formation and epithelial–mesenchymal transition

(2015) Ronan Russell et al.   Nature Communications

Smarter drugs emerging in pancreatic cancer therapy

(2014) A. Kleger et al.   ANNALS OF ONCOLOGY

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

(2014) M. Hidalgo et al.   Cancer Discovery

Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis

(2013) Meritxell Huch et al.   EMBO JOURNAL

Comparing Statistical Methods for Quantifying Drug Sensitivity Based on In Vitro Dose–Response Assays

(2011) Shuguang Huang et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES